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Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic started in 
December 2019 and still is a major global health challenge. Lockdown measures and social distanc-
ing sparked a global shift towards online learning, which deeply impacted universities’ daily life, 
and the University of Barcelona (UB) was not an exception. Accordingly, we aimed to determine 
the impact of the SARS-CoV-2 pandemic at the UB. To that end, we performed a cross-sectional 
study on a sample of 2784 UB members (n = 52,529). Participants answered a brief, ad hoc, online 
epidemiological questionnaire and provided a nasal swab for reverse transcription polymerase 
chain reaction (RT-PCR) SARS-CoV-2 analysis and a venous blood sample for SARS-CoV-2 IgG an-
tibody assay. Total prevalence of SARS-CoV-2 infection (positive RT-PCR or positive IgG) was 
14.9% (95%CI 13.3 to 17.0%). Forty-four participants (1.6%, 95%CI: 1.2–2.1%) were positive for 
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SARS-CoV-2 RT-PCR. IgG against SARS-CoV-2 was observed in 12.8% (95%CI: 11.6–14.1%) of par-
ticipants. Overall, while waiting for population vaccination and/or increased herd immunity, we 
should concentrate on identifying and isolating new cases and their contacts. 
Keywords: coronavirus; seroprevalence; SARS-CoV-2; infection status; university community; 
COVID-19 prevalence; faculty members; Spain; students; administrative and service staff 
 
1. Introduction 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic re-
mains a major global health challenge which limits universities’ academic and research 
activities, thereby forcing the implementation of new teaching and working paradigms 
(online distance learning, etc.). Interestingly, SARS-CoV-2 transmission at the university 
has been associated with the well documented infectivity of asymptomatic individuals, 
many of them being pre-symptomatic with high viral loads [1–6]. Those asymptomatic 
carriers are likely to be responsible for as many as 44% of new infections [7]. Although 
closing campuses and switching to fully remote education will reduce SARS-CoV-2 trans-
mission, this measure of force might have impacts on education quality, graduation rates 
and revenue [8]. 
Indeed, the COVID-19 pandemic has changed university life. On-site activities have 
been reduced only to those considered essential and requiring face-to-face attendance (i.e., 
demonstrations). While these challenges posed by the pandemic have created unique 
communication opportunities for university communities, it must be recognized that, for 
many courses (e.g., organic chemistry), it is challenging to complete an academic year 
taught exclusively online, and that professional and academic skills training have been 
jeopardized by the pandemic. In addition, online administrative procedures and telecom-
muting means had to be provided to university employees, which meant a considerable 
investment in a time of economic turmoil. Within this scenario, the main concerns are the 
impacts that this temporary closure may have on the quality of education and the aca-
demic performance of students. Overall, while it is important to maintain students’ aca-
demic performance during this crisis period [9], public health cannot be compromised by 
an in loco education system favoring SARS-CoV-2 transmission; thus, many considera-
tions should be balanced before deciding to reopen the university. 
The University of Barcelona (UB) is a public Catalan university founded in 1450 and 
is the largest university in Catalonia. It is frequently ranked as the first-rated university in 
the country [10]. During the last academic year (2019/20) the UB community was com-
prised of 69,353 members, including 61,119 students (~17% foreign) distributed as 41,750 
bachelor’s degree students, 5337 graduate students, 4582 pre-doctoral researchers and 
8,941 postgraduate students [11]. In addition, the UB employs 2409 administrative and 
service staff (ASS), and 5825 faculty members (FM), of which 930 are clinical faculty mem-
bers (CFM) associated with the three main university hospitals (Clínic, Bellvitge and Sant 
Joan de Déu) and 11 corporate health centers [12] of the UB. Altogether, UB members are 
distributed all through an institutional structure consisting of 16 schools organized into 
six university Campuses [13], the Barcelona Science Park [14], 17 UB research institutes 
and other 12 research institutes [15]. 
Antibodies are a biomarker for total or partial immunity, so their prevalence can re-
veal the proportion of the population that remains susceptible to the virus. Knowing the 
prevalence of infection (active or passed) constitutes a powerful tool for overviewing the 
pandemic’s impact at the UB to guide academic authorities toward the re-opening of on-
site activities progressively.   
Int. J. Environ. Res. Public Health 2021, 18, 6526 3 of 12 
 
 
2. Materials and Methods 
2.1. Study Design and Participants 
This was a cross-sectional study conducted among UB members between 14 Decem-
ber 2020 and 25 February 2021. According to a nationwide, population-based seroepide-
miological study (ENE-COVID Study) [16], we expected a SARS-CoV-2 seroprevalence of 
7.5% for students and 12% or higher for clinical faculty members. In addition, we assumed 
a 30% non-response rate. Thus, to reach a final overall sample size of 3450 individuals, we 
estimated that an initial sample size of 4944 participants was required. On 9 December 
2020, 4944 UB members were randomly selected and invited to participate by email. After 
three reminders, only 370 individuals participated in the study, thereby providing rate of 
participation of 7.5% (almost ten-times less to the expected one). Consequently, on 1 Feb-
ruary 2021, after this initial attempt, a new sample of 4944 UB members was randomly 
selected and invited to participate by email with similar results. Finally, in view of this 
low participation rate, we decided to contact and invite the remaining UB population to 
participate in two other successive waves, on 8 February (n = 26,671) and 15 February 2021 
(n = 15,961). A final sample of 2784 participants participated (Figure 1). UB members were 
contacted by the information in the most recent census (updated for the UB President’s 
election in December 2020). 
 
Figure 1. Overview of the flow chart of UB members involved in the study. 
2.2. Logistics Procedure 
The email briefly introduced the study and requested participation, which entailed 
free PCR and IgG testing. Once a participant accepted online, he/she was required to an-
swer a short online epidemiological questionnaire. This questionnaire (see Table A1) gath-
ered information about sociodemographic variables, self-reported clinical background 
(including estimated body masa index and COVID-19-related symptoms), lifestyle habits 
(i.e., tobacco and alcohol use), previous screening for SARS-CoV-2 (i.e., RT-PCR and/or 
serology) and risk of SARS-CoV-2 infection (i.e., contact with infected people). Thereafter, 
the participant was able to choose the day and the hour for sample collection in one of the 
three UB points of care in the city—two at the UB Medical School campuses (Clínic and 
Bellvitge) and one at UB Health Services (Pedralbes Campus). Next, the participant re-
ceived an email with the appointment. If needed, the participant was able to amend the 
appointment with the support of the study personnel.   
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2.3. Sample Collection 
Participants present at the UB points of care were first asked to sign the written in-
formed consent to participate in the study and review the online epidemiological ques-
tionnaire with an interviewer of the study team. Thereafter, trained nurses obtained a na-
sal sample with a mid-turbinate swab for RT-PCR testing [17] and a venous blood sample 
(3 mL) for detection of SARS-CoV-2 antibodies. Samples were assigned numeric codes for 
de-identification purposes and were processed by the Microbiology Service of the Bell-
vitge University Hospital. When a positive RT-PCR result was found, the participant was 
immediately contacted and referred to the COVID-19 agent from the Catalan Health Ser-
vice, thereby following the established COVID-19 protocol. 
2.4. SARS-CoV-2 Detection by RT-PCR 
SARS-CoV-2 active infection was studied on mid-turbinate nasal swabs by RT-PCR 
using the TaqPathTM® COVID-19 assay (Thermo Fisher Scientific, Madrid, Spain). Values 
below 40 cycles were taken as positive results for SARS-CoV-2. Presumptive identification 
of cases belonging to the variant of concern (VOC) 202012/01 (B.1.177 lineage) [18] was 
assessed by TaqPathTM® when both viral targets ORF1ab and N yielded positive ampli-
fications while the S target provided a negative result [19]. 
2.5. Detection of SARS-CoV-2 Antibodies 
Detection of SARS-CoV-2 antibodies in serum samples was carried out by the El-
ecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay (Roche Diagnostics 
GmbH, Mannheim, Germany), used for the in vitro qualitative detection of antibodies 
(including IgG) against SARS-CoV-2 in human serum and plasma. The assay uses a re-
combinant protein representing the nucleocapsid (N) antigen in a double-antigen sand-
wich assay format, which favors detection of high affinity antibodies against SARS-CoV-
2. Elecsys® Anti-SARS-CoV-2 detects antibody titers, which have been shown to positively 
correlate with neutralizing antibodies in neutralization assays [20,21]. 
2.6. Statistical Analysis 
Participants in our study were randomly selected through stratified one-stage sam-
pling from the entire UB population. Due to the heterogeneity of sociodemographic char-
acteristics across the UB population, stratification was based on students, ASS and faculty 
members. This last group was also divided into clinical faculty and non-clinical faculty 
members (i.e., CFM and FM) due to an expected higher exposition to SARS-CoV-2 among 
the first. By using this four-group stratification, no UB member was left out of the study. 
The sample size by the group was determined for an underlying SARS-CoV-2 seropreva-
lence of 7.5% or higher for students, ASS, FM and CFM, according to a nationwide, pop-
ulation-based seroepidemiological study (ENE-COVID Study) [16], and 12% or higher for 
clinical faculty. 
Baseline characteristics of participants by group (i.e., students, ASS, FM and CFM) 
are described using mean and standard deviation for continuous variables and frequen-
cies for categorical variables. Prevalence of asymptomatic SARS-CoV-2 infection is re-
ported as a percentage of subjects with a positive RT-PCR. Seroprevalence was estimated 
as the percentage of subjects with a positive serology test. Global RT-PCR-positive preva-
lence and global gseroprevalence were estimated using sampling weights. Exact 95% bi-
nomial confidence intervals were calculated for each prevalence. For sensitivity, preva-
lence of asymptomatic SARS-CoV-2 infection and seroprevalence were estimated by re-
cruitment period, and by health-related faculty (i.e., medicine, biology, psychology and 
pharmacy). Data analysis was carried out using R statistical software [22].  
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2.7. Role of the Funding Source 
The funders had no role in the design, analysis, interpretation or writing. The first 
three authors (S.V., A.O. and E.F.) and the senior author (F.C.) had full access to all the 
data, and they had final control over the decision to submit this paper for publication. 
3. Results 
3.1. Baseline Characteristics 
From the UB community members invited to participate via email (52,529 members), 
only 3243 enrolled into the study, which represents 6.2% of the UB population invited 
(Figure 1). The list of enrolled UB participants was then refined by searching redundancy 
(duplicities, etc.) and/or information mismatches; thus, we ended with a study population 
of 3123 UB members with a complete epidemiological questionnaire. From these, we were 
unable to obtain biological samples (i.e., nasal swap and blood sample) from 339 individ-
uals, thereby ending in a final study population of 2784 participants providing both a val-
idated epidemiological questionnaire and SARS-CoV-2 analytical result (Figure 1). 
The sample (n = 2784) was constituted by 1206 graduate and undergraduate students, 
699 ASSs, 793 FMs and 86 CFMs (Table 1), with a high proportion of women (65.3%). The 
mean age of the participating students was 23.1 (SD, 6.3) years old; the mean age of ASS, 
FM and CFM was 49.1 (SD, 0.4) years old (Table 1), which is near that reported in the UB 
records (i.e., 48.5 ± 1.2 years old). Baseline characteristics of the participants by university 
group are shown in Table 1. Interestingly, 54% of participants declared daily alcohol con-
sumption and 13% were current smokers, and less than 11% and 7% declared having in-
creased use during the pandemic, respectively (see Table 1). 
Table 1. Baseline characteristics of participants based on the epidemiological questionnaire. 
  
Students 
n = 1206 
ASS 
n = 699 
FM 
n = 793 
CFM 
n = 86 
Age, years  mean (sd) 23.1 (6.3) 49.3 (9.4) 48.8 (11.3) 50.4 (10.8) 
Gender, Male/Female n (%)/n (%) 334 (28)/872 (72) 222 (32)/477 (68) 
369 (46.5)/424 
(53.5) 
40 (46.5)/46 (53.5) 
BMI, kg/m²      
Underweight, < 18 n (%) 62 (5) 5 (1) 14 (2) 1 (1) 
Normal weight, 18 < 25 n (%) 937 (78) 346 (50) 452 (57) 52 (61) 
Overweight, 25 < 30 n (%) 172 (14) 238 (34) 266 (34) 27 (31) 
Obesity, ≥ 30 n (%) 34 (3) 108 (16) 59 (7) 6 (7) 
Clinical background (yes): n (%)     
Cancer n (%) 2 (0) 3 (0) 1 (0) 0 (0) 
Cardiovascular disease  
(includes hypertension) 
n (%) 9 (1) 73 (10) 89 (11) 13 (15) 
Endocrine disease (diabetes) n (%) 2 (0) 15 (2) 8 (1) 0 (0) 
Immunocompromised n (%) 3 (0) 12 (2) 9 (1) 1 (1) 
Liver diseases n (%) 2 (0) 6 (1) 2 (0) 0 (0) 
Pulmonary disease n (%) 38 (3) 44 (6) 26 (3) 2 (2) 
Renal disease n (%) 0 (0) 2 (0) 6 (1) 1 (1) 
Lifestyle habits:      
Alcohol consumption, yes 
Increased during pandemic, yes 
n (%) 
n(%) 
502 (42)/ 
57 (11) 
397 (57) 
47 (12) 
560 (71) 
59 (10) 
52 (61) 
8 (15) 
Smoke tobacco, yes  n (%) 147 (12) 123 (18) 82 (10) 9 (11) 
Increased during pandemic, yes n (%) 71 (6) 47 (7) 35 (4) 1 (1) 
Previous screening for SARS-CoV-
2: 
     
At least one RT-PCR, yes n (%) 626 (52) 263 (38) 292 (37) 44 (51) 
At least one RT-PCR-positive, yes n (%) 68 (11) 29 (11) 19 (7) 4 (9) 
At least one serology study, yes n (%) 232 (19) 78 (11) 126 (16) 16 (19) 
At least one serology-positive 
study, yes 
n (%) 35 (13) 15 (16) 12 (9) 4 (9) 
Risk of SARS-CoV-2 infection:      
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Direct contact with infected people, 
yes 
n (%) 154 (23) 84 (13) 79 (12) 10 (13) 
Abbreviations: ASS, administrative and service staff; FM, faculty members; CFM, clinical faculty members; BMI, body 
mass index. 
From participants that declared to have been previously tested for SARS-CoV-2 by 
RT-PCR (44%) or serology analysis (16%), 10% of them reported a positive RT-PCR and 
13% informed us about positive SARS-CoV-2 serology (see Table 1 for detailed stratifica-
tion). Interestingly, 16% of participants declared being in direct contact with infected peo-
ple (Table 1). Among the 2784 participants previously tested for SARS-CoV-2 with at least 
one RT-PCR (Table 1), 1225 (44.0%, 95%CI: 42.2–45.9%) provided information about 
COVID-19-related symptoms and signs (Table 2); thus, 360 (29.4%) reported at least one 
COVID-19-related symptom. The more frequent symptoms were fever (14.4%) and cough 
(11.6%); the less frequent were ageusia (2.78%) and nausea (3.26%) (Table 2). 
Table 2. COVID-19-related symptoms during 2020 in participants with at least one previous RT-
PCR. 
3.2. SARS-CoV-2 Infection Prevalence 
Total prevalence of SARS-CoV-2 infection (positive RT-PCR or positive IgG) was 
14.9% (95%CI 13.3 to 17.0%). The prevalence of SARS-CoV-2 infection determined by RT-
PCR (active infection) was 1.59% (44 out of 2775, 95%CI: 1.18–2.12%). No differences arose 
by groups within the UB community. Students had the highest prevalence (2.08%, 95%CI: 
1.35–3.06%). ASS and FM showed prevalences of 1.0% (95%CI: 0.40–2.06%) and 1.52% 
(95%CI: 0.79–2.64%), respectively. There were no SARS-CoV-2 RT-PCR-positive partici-
pants among the CFM. Finally, no differences in active infection were found by sex (1.03%, 
95%CI: 1.54–2.22% female; and 0.95%, 95%CI: 1.66–2.69% male). Global SARS-CoV-2 in-
fection prevalence estimated using sampling weights and SARS-CoV-2 infection preva-
lence by UB community groups are shown in Figure 2. 
  
Students 
n = 626 
ASS 
n = 263 
FM 
n = 292 
CFM 
n = 44 
Fever (yes) n (%) 102 (16.3%)  38 (14.4%)  33 (11.3%)  4 (9.1%)  
Cough (yes) n (%) 77 (12.3%)  35 (13.3%)  26 (8.9%)  4 (9.1%)  
Anosmia (yes) n (%) 35 (5.6%)  10 (3.8%)  5 (1.7%)  1 (2.3%)  
Ageusia (yes) n (%) 26 (4.2%)  5 (1.9%)  2 (0.7%)  1 (2.3%)  
Shortness of breath (yes) n (%) 29 (4.6%)  8 (3.0%)  8 (2.7%)  3 (6.8%) 
Sore throat (yes) n (%) 54 (8.6%)  21 (8.0%)  12 (4.1%)  0 (0.0%)  
Fatigue (yes) n (%) 55 (8.8%)  20 (7.6%)  20 (6.8%)  2 (4.6%)  
Nausea (yes) n (%) 18 (2.9%)  11 (4.2%)  11 (3.8%)  0 (0.0%)  
Diarrhoea (yes) n (%) 50 (8.0%)  29 (11.0%)  15 (5.1%)  1 (2.3%)  
Arthralgia (yes) n (%) 56 (8.9%)  24 (9.1%)  12 (4.1%)  1 (2.3%)  
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Figure 2. SARS-CoV-2 infection prevalence (assayed by RT-PCR and IgG serology) estimated us-
ing sampling weights by UB community groups. Results are expressed as percentages of subjects 
showing positive RT-PCR for SARS-CoV-2 (prevalence of current infection) or antibodies against 
SARS-CoV-2 (seroprevalence or prevalence of past infection) with 95% Cis, according to UB com-
munity groups: students, administrative and service staff (ASS); faculty members (FM) and clini-
cal faculty members (CFM). A vertical line represents the overall prevalence (RT-PCR or serology) 
and the dotted lines the 95%CI. 
At the time of the study, none of the participants were yet vaccinated; thus, the N anti-
gen was enough to detect immunity after SARS-CoV-2 infection. The overall prevalence of 
past SARS-CoV-2 infection was 12.8% (356 out of 2775, 95%CI: 11.6–14.1%). The seropreva-
lence among students was higher (15.4%, 95%CI: 13.4–17.6%) and statistically significant 
compared to FM (9.0%, 95%CI: 7.1–11.2%; p < 0.05). The seroprevalence among ASS was 
12.9% (95%CI: 10.5–15.6%), and it was 11.8% (95%CI: 5.8–20.6%) among CFM. By sex, the 
prevalence of past SARS-CoV-2 infection was 11.66%, 95%CI: 13.19–14.84%, in females; and 
10.15%, 95%CI: 12.15–14.38%, in males. Global seroprevalence estimated using sampling 
weights and seroprevalence by UB community groups are shown in Figure 2. 
Importantly, while the 44 participants with positive SARS-CoV-2 RT-PCR assays 
were clinically asymptomatic, six out of 44 showed the presumptive VOC 202012/01 gen-
otype, first described in UK in early December 2020 [19]. In two out of these six cases, 
antibody detection was positive, and it was negative in the other four cases. All six partic-
ipants were detected in February 2021, a period of greater detection of this viral variant in 
our area. 
3.3. Asymptomatic COVID Infections 
From the 44 asymptomatic participants who were RT-PCR-positive for SARS-CoV-2, 
38 (86%) also carried IgG antibodies. Therefore, only six participants (four students and 
two FMs) were considered to have early infections (RT-PCR-positive but negative sero-
logical assays). These individuals constituted the 0.22% (6 out of 2775, 95%CI: 0.10–0.47%), 
likely considered as asymptomatic cases with high viral loads, and thus potential trans-
mitters, as discussed earlier [1–6]. 
Interestingly, among participants who declared at least one COVID-19-related symp-
tom (n = 360), the proportions of participants reporting a seropositive study were 29.2% 
(95%CI: 22.9–36.0%) among students; 30.1% (95%CI: 20.5–41.2%) among ASS, 25.7% 
(95%CI: 16.0–37.6%) among FC and 37.5% (just 3 out of 8, 95%CI: 8.5–75.51%) among CFM. 
By sex, 27.4%, 95%CI: 22.1–33.3% (71 out of 259) were female; 32.7%, 95%CI: 23.7–42.7% 
(33 out of 101) were male. From those, positive RT-PCR tests were reported by only 10 
participants (five males and five females). 
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4. Discussion 
The findings from this study (carried out mainly in February 2021, during the pan-
demic’s third wave in Spain) indicate a relatively low prevalence of SARS-CoV-2 infection 
within the UB community. We did not observe substantial differences in SARS-CoV-2 in-
fection by community group or sex, other than between students and FMs. All partici-
pants who had positive RT-PCR tests were asymptomatic. However, as time goes by and 
SARS-CoV-2 infections spread, this low prevalence will grow, and together with commu-
nity vaccination will contribute to herd immunity. Accordingly, a close follow up of the 
pandemic’s progression within the next months will allow us to progressively adapt the 
teaching and research activities towards normality. 
Asymptomatic and paucymptomatic individuals can unknowingly transmit the vi-
rus and fuel covert outbreaks [5,23,24]. Our results show that the prevalence of asympto-
matic SARS-CoV-2 infected individuals (1.94%) was low, as expected, but this finding 
does not guarantee safety. Our results cannot rule out that close contact with people with 
COVID-19, and particularly those in the same household, increases viral transmission. 
The early detection of asymptomatic infections is vital for mitigating viral transmission 
and containing outbreaks. Therefore, the information about asymptomatic SARS-CoV-2 
infected individuals is essential for guiding university directives regarding re-opening on-
site activities. 
Serological screening is the best tool to determine the spread of an infectious disease, 
particularly in the presence of asymptomatic cases or incomplete ascertainment of those 
with symptoms [16,25]. The seroprevalence found (12.8%) was greater than that estimated 
in Catalonia in December 2020, 9.2% (95%CI: 7.7–11.0)—by gender, 8.6% (95%CI: 6.9–10.5) 
in males and 9.8% (95%CI: 8.1–11.8) in females [16]; and greater than the seroprevalence 
estimated in Spain in the same study (overall population, 7.1% (95%CI: 6.7–7.6), and by 
gender, 6.7% (95%CI: 6.2–7.2) in males and 7.5% (95%CI: 6.9–8.0) in females). Interestingly, 
the results reported here are in line with these recently reported for the SARS-CoV-2 se-
roprevalence in 2905 university students from five different universities within England 
(17.8%, 95%CI, 16.5–19.3), ranging between 7.6 and 29.7% [26]. 
Detection of SARS-CoV-2 infection performed simultaneously by RT-PCR and IgG 
serology provides a global view of the pandemic’s impact within the university commu-
nity. Asymptomatic SARS-CoV-2 infected people cannot be ignored, and the low sero-
prevalence found is plainly insufficient to be considered as satisfactory herd immunity. 
Considering the global situation (including economic recession) and while we wait for 
most of the population to be vaccinated and/or for herd immunity to be achieved, our 
results should be interpreted as sufficient to support the current nonpharmacologic pre-
ventive measures taken, such as mask wearing, social distancing, hand hygiene (with hy-
droalcoholic gels), ventilated spaces and “sheltering in place” for a minimum of 10 days 
if in contact with an infected person. Extensive social distancing with a mandatory mask-
wearing policy can prevent most COVID-19 cases on college campuses and is very cost-
effective; and routine laboratory testing would prevent disease spread, but would require 
lower-cost tests combined with markedly increased capacity to be feasible [27]. However, 
given the lack of logistical and economic competences for implementing screening tests 
of SARS-CoV-2 infection, all this means that the university officers will face the challenge 
soon of slowly returning to pre-pandemic university activity. 
Online distance learning should be carried on, and on-site activities in UB should be 
only considered for those deemed essential. Although the university has attempted to 
maintain normality for their students through online lectures and video conferences, and 
by getting involved in the delivery of telehealth services, FMs must try to adapt to the 
new reality of the online classes with the aim of maintaining the level of educational ex-
cellence. Furthermore, the student–teacher interaction online is the new reality and must 
be accepted. This pandemic situation should be understood as an opportunity to develop 
new learning methods. In the future, online classes will be integrated as another pedagog-
ical tool, and future lectures will be implemented for students worldwide. Hence, online 
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classes’ innovation requires implementing procedures that potentiate real-time interac-
tion with students. This should be one of our goals. The university should facilitate the 
training of professional skills in this reality and provide the means to carry it out [28]. 
Telecommuting is a measure that should be kept for a percentage of staff. Therefore, the 
procedures for user interaction, that of both FMs and students, should be improved or 
implemented. This “new reality” of the rapid university education transformation due to 
the COVID-19 crisis should be understood as an opportunity for positive and sustained 
change. The university must integrate the digital transformation gained during the 
COVID-19 pandemic in future academic courses, and must ensure that it continues, in-
stead of going back to the pre-COVID status quo [28]. Importantly, the UB is a research-
intensive institution operating in fields, including experimental and health sciences. Thus, 
the COVID-19 pandemic also represented a challenge for these UB research activities re-
quiring in-person attendance. Indeed, research activities that are deemed critical (for ex-
ample, animal research) have been permitted for designated personnel at designated 
times, and always with strict adherence to social distancing and preventive measures. 
Subsequently, several measures were undertaken to maintain and progressively increase 
baseline research. Overall, the COVID-19 pandemic represents a great challenge for the 
development of both teaching and research activities at our university. 
Some limitations need to be considered for the interpretation of the results of this 
cross-sectional study. Whilst we intended to obtain a representative sample of the univer-
sity community, the low participation rate prompted us to finally invite all members of 
the target community to participate, thereby allowing us to obtain a sufficient sample size. 
The final sample obtained was representative across several baseline characteristics, such 
as sex and age, of the overall university population, but not of community groups and 
schools. This might imply that generalization to the overall UB population or more gen-
eral university populations must be done with caution. Finally, other potential limitations 
of the study should be considered—for instance, the fact that the clinical background data 
shown in Tables 1 and 2 are based on self-reporting by participants (i.e., not formally rec-
orded by a clinician); thus, this information should be considered accordingly. In addition, 
our questionnaire did not record information regarding the preventive measures taken by 
participants during their daily tasks. Overall, the focus of the study was to provide a 
global perspective of the pandemic’s impact on the UB community. Thus, although we 
studied heterogeneity across the UB community groups (i.e., students, ASS, FM and 
CFM), we did not account for the heterogeneity of transmission within each group (for 
example, students living outside of Barcelona vs. students living in Barcelona), which 
would have required additional and unavailable data. This could be of importance, since 
the UB welcomes a high percentage of students from other Spanish cities and from abroad, 
who during the lock-down and permanent closing of the university mostly stayed home. 
However, this study is, to the best of our knowledge, the first to assess prevalence of 
SARS-CoV-2 infection at a public university in Spain, and one of the few in the interna-
tional literature [26]. 
5. Conclusions 
The estimated prevalence of SARS-CoV-2 infection was low within UB’s community 
at the time we performed the study (i.e., February 2021). While these results do not suffice 
to deescalate COVID-19 preventive measures (i.e., mask wearing, social distancing and 
ventilated spaces), right now, the continuous increase of SARS-CoV-2 infection prevalence 
and community vaccination will contribute to achieving the minimal herd immunity 
needed to start taking progressive measures to adapt the teaching and research activities 
towards normality along the next academic year. 
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Appendix A 
Table A1. Online epidemiological questionnaire. 
Sociodemographic 
•Age 
•Gender 
•Collective UB (student, faculty, administrative) 
•Weight 
•Height 
•Level of studies 
Clinical background 
•Cancer 
•Cardiovascular disease (includes hypertension) 
•Endocrine disease (includes diabetes) 
•Immunocompromised 
•Liver diseases 
•Pulmonary disease 
•Renal disease 
Background SARS-CoV-2 
infection 
•No / suspected / confirmed 
In case of suspected or confirmed: 
•Date of first symptom 
•Symptoms (fever, chills, severe tiredness, sore throat, cough, arthralgia, short-
ness of breath, heada che, anosmia or ageusia, and nausea, vomiting, or diar-
rhoea) sore throat, cough, arthralgia, shortness  
Previous screening for 
SARS-CoV-2 
•Previous screening for SARS-CoV-2 
•PCR (date, positive/negative) 
•Serology (date, positive/negative) 
Risk of SARS-CoV-2 infec-
tion 
Direct contact/s with people with COVID 
Lifestyles 
•Alcohol (previous / during pandemic) 
•Smoke tobacco (previous / during pandemic) 
•Other drugs 
Table A2. Members of the UB-GTMS COVID-19 group. 
University of Barcelona: 
Amparo Asensi, Montse Bachs, Maria Dolors Baena, Silvia Costa Abós, Cristina Cruz Gómez, 
Antoni Forés, Ester Fusté Domínguez, Rocio Escobar Miranda, Antonio Gar-cía-Honrubia, 
Anna Gargallo, Eva Garrido, Isabella Gastalgo, Miquel Lizandra, José López López, Maria An-
tonia Martínez Momblan, Vinyet Robles, Xavier Roca, José L. Rosa-López, Josep Maria Sierra 
Artigosa, Gonzalo Silva-Robledo, Avelina Tortosa, An-toni Trilla-García, Marta Valle,  
Gerència Territorial Metropolitana Sud (GTMS):  
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Encarna Grifell-Martín 
Clinical Research Support Unit-[HUB·IDIBELL]: 
Thiago Carnaval 
Information and Communication Technologies Department-Catalan Institute of Health: 
Pau Casals-Villena, Manel Domingo-Rodríguez, Nacho Nieto 
Bellvitge University Hospital: 
Anna Carrera-Salinas, Aida González-Díaz, Daniel Vázquez-Sánchez 
UICEC-Bellvitge University Hospital: 
Ana Gainza, Angela Garrido, Pilar Hereu, Nadia Llavero, Eva Llosa, Mireia Santllorente 
Nursing-University of Barcelona: 
Sonia Aguirre Álvarez, Sergio Alonso, Mónica Tania Anguita Amador, Sonia Ayuso Margañón, 
Nadia Azzouz Balich, Núria Campanera Moliné, Carmen Cañas Aranda, Jessica Castaño Ca-
muñez, Paloma Castillo, Alba Cuartero, Joan Maria Estrada Masllorens, Anabelen Fernández-
Cervilla, Daniela C. de Freitas-Vieira, Elvira García Carulla, Verónica Gimenez Villa, Julia Gon-
zález Vaca, Marta González Martínez, Eva M. Guix-Comellas, Ana Lanau Roig, Cristina La-
serna-Jiménez, Nerea Latorre Feliu, Mireia Lopez-Poyato, Laura Manzano-Benito, Laura Mar-
tin-Moreno, Eugenia Mellado-Pau, Paloma Pifarre Montaner, José M. Montero, Sabah L. el Mo-
rabiti, Marta del Moral, Yolanda Martos, M. Carmen Olmos Palenzuela, Marc Pañero, Celine 
Primiceri-Sánchez, Angela Puchercos Ferrer, Andrea Roman-Martinez, Andrea Recacha 
Robredo, Carlota Riba, Marta Romero García, Samuel Romero Martínez, Antonio Rosa Castillo, 
Anabelen Rubio, José Luis Sánchez-Ceba, José A. Sarria-Guerrero, Cristina Sanz Mellado, Ange-
les Saz Roy, Sara Tejero Bernardo, Gloria Timoneda-Gracia, Andrea Urbina Moral 
Oficina de Seguretat, Salut i Medi Ambient (OSSMA)—University of Barcelona: 
Begoña Castillejos, Oriol Grasas-Llorens, Mariona Mas-Calderer, Pedro Moreno Arribas, Susana 
Sánchez Redondo, Xavi Trullàs Escoda, 
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